The emerging role of artificial intelligence in preoperative prediction of surgical margin status in breast cancer surgery [0.03%]
人工智能在乳腺癌手术前预测切缘状态中的新兴作用
Mahtab Khajeh,Mohammad Amin Shahram
Mahtab Khajeh
Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count? [0.03%]
乳腺癌药物审批临床试验中的患者报告结果您重视了吗？
Samuel Margolis,Andre Naguib Guirguis,Catherine Lee et al.
Samuel Margolis et al.
Purpose: Patient-reported outcomes (PROs) inform benefit-risk tradeoffs in breast cancer treatment, yet reporting quality across registration trials remains incompletely characterized. ...
Self-reported racial and ethnic discrimination in patient-provider interactions and the initiation of adjuvant therapies for breast cancer in the pathways study [0.03%]
路径研究中患者与提供者互动中的自我报告的种族和族裔歧视与乳腺癌辅助治疗的启动有关
Kevin R Bitsie,Thomas A Pearson,Marilyn L Kwan et al.
Kevin R Bitsie et al.
Purpose: Despite advancements in breast cancer adjuvant therapies, some patients with indications may not receive treatment. We examined the association of self-reported racial/ethnic discrimination in patient-provider in...
Association of tumor Schwann cells with epithelial-mesenchymal transition and immune-suppressive microenvironment in triple-negative breast cancer [0.03%]
肿瘤施万细胞与三阴性乳腺癌中的上皮间质转化和免疫抑制微环境的关系
Kei Kawashima,Eslam A Elsaedy,Masanori Oshi et al.
Kei Kawashima et al.
Purpose: Tumor-associated nerves have recently emerged as an understudied key regulator of cancer biology. However, its quantification using histological or transcriptomic approaches is challenging because their small dia...
Interstitial lung disease in metastatic breast cancer: a landscape review using SEER-Medicare [0.03%]
基于SEER- medicare的乳腺癌转移所致间质性肺病的文献回顾
Laura C Pinheiro,Anjile An,Chrystal A Landry et al.
Laura C Pinheiro et al.
Introduction: Interstitial lung disease (ILD) is a serious side effect of certain mBC treatments, but our understanding of its prevalence outside of clinical trials and treatment-specific studies is limited. We sought to ...
Invasive lobular breast cancer in young patients without adjuvant systemic treatment: 15-year survival outcomes [0.03%]
年轻乳腺浸润性小叶癌患者未接受系统性辅助治疗的15年生存结果分析
R A B Voorthuis,M Opdam,N D Ter Hoeve et al.
R A B Voorthuis et al.
Purpose: Invasive lobular carcinoma (ILC) of the breast typically affects older women. As a result, there is limited research on prognosis and prognostic factors in young women with ILC. Here we set out to determine the l...
Optimising screening intervals and BI-RADS management pathways in ultrasound-based breast cancer screening: real-world evidence from Shenzhen (2018-2023) [0.03%]
基于超声的乳腺癌筛查中优化筛查间隔和BI-RADS管理路径：来自深圳（2018-2023）的现实世界证据
Wanyi Sun,Huan Li,Xuelian Zhao et al.
Wanyi Sun et al.
Purpose: To identify screening intervals and BI-RADS-specific management pathways that balance cancer detection yield against recall burden in ultrasound-based breast cancer screening in China. ...
Locoregional recurrence and mortality after breast cancer surgery in patients aged 85 and older [0.03%]
85岁以上乳腺癌手术患者的局部区域复发和死亡率
David Foulad,Jacqueline Tsai,Ingrid Luo et al.
David Foulad et al.
Purpose: Life expectancy is increasing and the number of patients age ≥ 85 with breast cancer (BC) may be on the rise. We report descriptive statistics regarding surgical management and outcomes in this cohort. ...
First-line treatment patterns and real-world survival outcomes in PD-L1-negative locally recurrent inoperable or metastatic triple-negative breast cancer in the United States [0.03%]
美国PD-L1阴性局部复发不可手术或转移性三阴性乳腺癌一线治疗模式及真实世界生存结局
Tiffany A Traina,Elizabeth Serra,Jerome Bedard et al.
Tiffany A Traina et al.
Purpose: Contemporary real-world data on treatment patterns and clinical outcomes in patients with programmed death ligand 1 (PD-L1)-negative locally recurrent inoperable or metastatic triple-negative breast cancer (lr/mT...